Differential response to Janus kinase inhibitors in refractory livedoid vasculopathy: Biomarker-guided therapy may improve clinical response

JAAD Int. 2025 Dec 10:24:318-319. doi: 10.1016/j.jdin.2025.11.024. eCollection 2026 Feb.

Guoqun Yu^{1

2}, Jinjin Zhu^{1

2}, Yuan Zhang^{1

2}, Fan Yang^{1

2}, Jing Yang^{1

2}, Juan Tao^{1

2}

¹ Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China.
² Hubei Engineering Research Center for Skin Repair and Theranostics, Wuhan, China.

No abstract available

Keywords: JAK activation; Janus kinase inhibitors; livedoid vasculopathy; off-label treatment; personalized therapy; refractory skin disease.